MosaiQ microarrays have been developed to meet the changing needs of donor testing laboratories.
Quotient is an active member of several global groups and collaborations that help shape the future diagnostic landscape. Our company constantly monitors the market, working with external groups so we can be proactive in incorporating new assays on MosaiQ to meet future demands.
We are currently in the process of developing molecular disease screening capabilities for MosaiQ, including NAT (nucleic acid testing). This will supplement the blood grouping and serological disease screening capabilities of the MosaiQ system.